about
Linezolid versus vancomycin for skin and soft tissue infectionsAntibiotics prior to amniotomy for reducing infectious morbidity in mother and infantLinezolid versus vancomycin for skin and soft tissue infectionsAntibiotics prior to amniotomy for reducing infectious morbidity in mother and infantReduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsBiomaterials with Antibacterial and Osteoinductive Properties to Repair Infected Bone DefectsDisruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic ResistanceQuantitative proteomic view associated with resistance to clinically important antibiotics in Gram-positive bacteria: a systematic reviewMechanisms of vancomycin resistance in Staphylococcus aureusStrategies for appropriate antibiotic use in intensive care unitRecent advances in engineering polyvalent biological interactionsInnovative qPCR using interfacial effects to enable low threshold cycle detection and inhibition relief.Targeting Antibiotic ResistanceMolecular Events for Promotion of Vancomycin Resistance in Vancomycin Intermediate Staphylococcus aureusA high-throughput screen identifies a new natural product with broad-spectrum antibacterial activityBenefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysisGut Microbiome of an 11th Century A.D. Pre-Columbian Andean MummyVancomycin-Associated Nephrotoxicity: The Obesity FactorVancomycin and nephrotoxicity: just another myth?Prevention of vancomycin induced nephrotoxicity: a review of preclinical data.Non-inferiority and networks: inferring efficacy from a web of data.Teicoplanin as an effective alternative to vancomycin for treatment of MRSA infection in Chinese population: a meta-analysis of randomized controlled trials.Linezolid versus vancomycin for skin and soft tissue infections.Safety profiles of old and new antimicrobials for the treatment of MRSA infections.Topical antimicrobials for burn infections - an updateVancomycin-associated nephrotoxicity: grave concern or death by character assassination?Vancomycin-resistant gram-positive cocci isolated from the saliva of wild songbirds.Revisiting Methicillin-Resistant Staphylococcus aureus Infections.Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study.The Whole Price of Vancomycin: Toxicities, Troughs, and TimeComparative Incidence of Nephrotoxicity by Age Group among Adult Patients Receiving Vancomycin.Draft Genomes of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Strain MM66 and MM66 Derivatives with Altered Vancomycin Resistance Levels.Questioning the accuracy of trough concentrations as surrogates for area under the curve in determining vancomycin safety.Accidental and iatrogenic causes of acute kidney injury.Host-guest chemistry of the peptidoglycanPolycyclic peptide therapeutics.Comparative genomics of community-acquired ST59 methicillin-resistant Staphylococcus aureus in Taiwan: novel mobile resistance structures with IS1216V.From stool transplants to next-generation microbiota therapeuticsTherapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients.Peptidoglycan: a post-genomic analysis.
P2860
Q24186563-9BA8DE58-9CE1-48B4-859B-C7F9255CC888Q24193196-4B27AFB4-B1B4-4541-90A5-8DF6178B523AQ24201228-45FB2C07-0C26-4814-9848-1C2C95875AB7Q24201732-142B766D-7886-4B50-BBD2-6A9F407EE2D2Q24646677-ACEE02A4-D715-47E5-AD4E-90943B3863EBQ26767374-39207DBC-4F0F-440D-8CF7-662FE748B9F0Q26771995-44499CF5-BC0E-449A-B767-130316D0A96DQ26796165-9490B3A3-5450-419C-B58E-719D35A41070Q26829312-3EA5EA18-77A7-4F4C-841A-0E94A40F3771Q27002517-6D9A20A4-078A-47C3-8B81-784611D1EE68Q27011503-0AD9AF54-170F-4D75-884F-8E32669BBF54Q27344266-37E9CC26-B906-44A1-971B-0E1599490214Q28078130-7BCD7CE6-7BEC-451E-8E65-5B38F0793EE2Q28078930-791A752C-FE0D-4C76-8DA6-9B04916AA4A2Q28480908-893EAABF-124D-424D-A368-0C988E780E13Q28534516-5F051B1D-10BA-41D2-936B-342C859E7DFEQ28548686-F526BDAE-5477-4A56-B88F-0B58B23F6076Q30278775-F4ADBECC-5D8D-49A2-AC19-AC3EB11C55E5Q30409849-2F62CD7D-D673-49CB-ACA2-9F5B62124E5CQ30569251-28510BCA-5AA5-4556-9F89-AB43629F377CQ31030399-27BA3849-9991-444C-9368-AD980EA83089Q31144203-ED44B334-FE7B-499D-ABA6-5C2CFF47AA8BQ33418740-F47D5D93-49AC-4FC3-992E-56353723E551Q33429168-35C7BD55-1E41-4BA9-9BC1-1075E7EC425DQ33600002-6CB6172F-0ABA-40E3-83A1-C0170B1C4781Q33617737-F7D454CE-E6B1-48DE-87E0-6ED4696D5D55Q33699395-FA2C3987-B1D7-495F-BCB1-DB4625F8D249Q33736523-17072DEA-0BD9-4742-9800-CC9C7E01DE1CQ33821959-AB1D0710-08FA-440C-B531-8C0BD39A409EQ33885191-371F5CC5-107F-40E4-A390-8B367C8BA0E7Q33939091-341A9710-FF11-4CAE-97C5-05F96185025EQ33949064-6863F421-5024-4D2A-B033-D8628C8E6052Q33949459-A8061933-6522-4B77-8D2A-D10EEE75C34CQ33954859-989AB74E-D766-4C07-93B9-E4F7C2F07020Q34013593-B889ECD3-7A87-4E8B-9250-6FADD997F53FQ34324717-86DFAD13-B45C-453D-B60C-0C1D09B5F1E8Q34447722-A4ED8A18-7474-4E59-932A-570A25E77F04Q34458414-C16F5545-27E9-49CA-BC8E-072C8CBD94F2Q34494676-FD00389F-00E5-439E-9546-6876AC9CF4A7Q34515182-5B1DB8DF-47AE-4525-9905-B4F44B02E2C6
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Vancomycin: a history.
@ast
Vancomycin: a history.
@en
Vancomycin: a history.
@nl
type
label
Vancomycin: a history.
@ast
Vancomycin: a history.
@en
Vancomycin: a history.
@nl
prefLabel
Vancomycin: a history.
@ast
Vancomycin: a history.
@en
Vancomycin: a history.
@nl
P356
P1476
Vancomycin: a history.
@en
P2093
Donald P Levine
P356
10.1086/491709
P407
P478
42 Suppl 1
P577
2006-01-01T00:00:00Z